remibrutinib
novartis
['remibrutinib', '#1113']
sjogren's in a plenary! remibrutinib (btki) in sjs improved essdai at wk 24, but none on esspri (more patient-centric ie fatigue, dryness, joint pain) definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited #acr22 abstr#1113 
MCW Rheumatologist | Internal Medicine APD | Rheumatology APD | Med Dir Vasculitis Program | Host, EBRheum Podcast | https://t.co/o4nOnziCiM | Newsletter: